Rigor Reviewed

Rigor-Reviewed Manuscript

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Name: Αlpha¹ Rigor Record — Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Item: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Rating: 96
Author: Αlpha¹

Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV, MajesTEC-3 Trial Investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

$Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 2 high issues for “Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.”$

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized controlled trial with rigorous design, clear reporting of ethics, demographics, and statistical methods. The main weaknesses are the absence of a data availability statement and lack of explicit statistical software identification, both minor reporting gaps.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered all eight dimensions; non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The reviewers agreed on all dimension statuses, with minor checklist discrepancies that did not affect outcomes.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior studies (MajesTEC-1, APOLLO, CASTOR, CARTITUDE-4) and explains the synergistic mechanism of teclistamab and daratumumab. The rationale for the study is clearly linked to the need for off-the-shelf, effective regimens in RRMM. Limitations of prior research are implicitly addressed by the design (e.g., comparing to standard of care).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study establishes a clear scientific premise by citing prior research on multiple myeloma treatments, including teclistamab and daratumumab, and provides a logical rationale for the combination.

Evidence

direct quote[Introduction, paragraph 2]

“Teclistamab, a bispecific antibody targeting CD3×BCMA, demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.”